Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merus N.V. - Common Shares (NQ: MRUS )

39.45 -0.20 (-0.50%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 638,973
Open 39.71
Bid (Size) 38.00 (2)
Ask (Size) 43.00 (1)
Prev. Close 39.65
Today's Range 38.71 - 40.12
52wk Range 33.60 - 61.61
Shares Outstanding 46,530,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's Going On With Merus Stock Monday?
Merus announced a research collaboration and license agreement with Biohaven. 
Via Benzinga
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
From Merus N.V.
Via GlobeNewswire

Performance

YTD
-6.74%
-6.74%
1 Month
-5.73%
-5.73%
3 Month
-23.55%
-23.55%
6 Month
-29.28%
-29.28%
1 Year
+13.10%
+13.10%

More News

Read More
TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday
Via Benzinga
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
From Merus N.V.
Via GlobeNewswire
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
From Merus N.V.
Via GlobeNewswire
Merus Scores Its First FDA Approval For Lung Cancer Drug
Via Benzinga
Exposures Product Safety
Jim Cramer: This Health Care Stock Is 'Very, Very Speculative'
Via Benzinga
Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
From Merus N.V.
Via GlobeNewswire
Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline
Via Benzinga
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
Via Benzinga
Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer
From Merus N.V.
Via GlobeNewswire
Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024
From Merus N.V.
Via GlobeNewswire
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Merus to Present at Upcoming Investor Conferences
From Merus N.V.
Via GlobeNewswire
Merus Receives FDA extension of PDUFA for zenocutuzumab
From Merus N.V.
Via GlobeNewswire
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC
From Merus N.V.
Via GlobeNewswire
Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024
From Merus N.V.
Via GlobeNewswire
Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference
From Merus N.V.
Via GlobeNewswire
MRUS Stock Earnings: Merus Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
From Merus N.V.
Via GlobeNewswire
Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
From Merus N.V.
Via GlobeNewswire
Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC
From Merus N.V.
Via GlobeNewswire
Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer
From Merus N.V.
Via GlobeNewswire
Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
From Merus N.V.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.